Peak Bio, Inc. Proceeds from Convertible Debt
Peak Bio, Inc. reported Proceeds from Convertible Debt of $2.20 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2024-06-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2024-06-25
- Peak Bio, Inc. proceeds from convertible debt for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Peak Bio, Inc. proceeds from convertible debt for the quarter ending 2022-12-31 was $0.00.
- Peak Bio, Inc. proceeds from convertible debt for the quarter ending 2022-09-30 was $1.25M.
- Peak Bio, Inc. proceeds from convertible debt for fiscal 2022 was $1.25M, a 153.87% increase from fiscal 2021.
- Peak Bio, Inc. proceeds from convertible debt for fiscal 2021 was $492.38K.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-25 | $2.20M 10-Q · filed 2024-06-25 | ||
| 2023-06-30 | $2.20M 10-Q · filed 2023-08-18 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-29 | $1.25M derived: sum of 2 quarters · filed 2024-06-25 | $1.25M 10-K · filed 2023-06-29 | |
| 2022-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-25 | $1.25M 10-Q · filed 2024-06-25 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-18 | |||
| 2021-12-31 | $492.38K 10-K · filed 2023-06-29 |